NASDAQ · EXELHealthcareBiotechnology

Exelixis financials

$58.65+0.48%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Jan 2
FY24
Jan 3
FY23
Dec 29
FY22
Dec 30
FY21
Dec 31
FY20
Jan 1
FY19
Jan 3
FY18
Dec 28
FY17
Dec 29
FY16
Dec 30
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B$987.5M$967.8M$853.8M$452.5M$191.5M
Gross profit$2.24B$2.09B$1.76B$1.55B$1.38B$951.3M$934.7M$827.5M$437.4M$184.9M
Gross margin96.4%96.5%96.0%96.4%96.3%96.3%96.6%96.9%96.7%96.6%
Operating income$872.2M$604.6M$170.9M$201.5M$286.7M$110.1M$369.5M$438.9M$165.9M-$28.1M
Net income$782.6M$521.3M$207.8M$182.3M$231.1M$111.8M$321.0M$690.1M$154.2M-$70.2M
Net margin33.7%24.0%11.4%11.3%16.1%11.3%33.2%80.8%34.1%−36.7%
Diluted EPS$2.78$1.76$0.65$0.56$0.72$0.35$1.02$2.21$0.49$-0.28
EBITDA$921.8M$718.8M$196.6M$222.4M$300.3M$119.2M$377.8M$443.8M$167.1M-$26.2M
Operating cash flow$884.3M$700.0M$333.3M$362.6M$400.8M$209.0M$527.0M$415.7M$165.6M$210.4M
Free cash flow$875.8M$671.5M$292.9M$224.2M$336.6M$178.6M$514.1M$382.4M$144.5M$208.7M
Diluted shares281.9M296.1M321.5M324.6M322.4M318.0M315.0M312.8M312.0M250.5M

Balance sheet

Period endJan 2Jan 3Dec 29Dec 30Dec 31Jan 1
Cash & equivalents$482.5M$217.4M$263.0M$501.2M$647.2M$319.2M
Short-term investments$576.6M$893.9M$732.3M$807.3M$819.9M$887.3M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$2.84B$2.95B$2.94B$3.07B$2.62B$2.14B
Total liabilities$683.1M$703.5M$678.4M$583.1M$405.6M$258.2M
Shareholders' equity$2.16B$2.24B$2.26B$2.49B$2.21B$1.88B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology